Cancer Vaccines Headed For Mainstream
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
No longer the odd cousins of traditional pharmaceutical applications, a host of therapeutic cancer vaccines is working through late-stage trials with real, life-extending data already reported and the potential to create a lot of action in the oncology sector.
You may also be interested in...
Top Oncology Partnering Opportunities: Immunotherapy In Vogue
Every November at Elsevier Business Intelligence’s Therapeutic Area Partnerships meeting in Boston, expert consultants present their pick of the top unpartnered oncology candidates. This year NewLink Genetics, Genelux, and Verastem are among those that made the grade.
FDA Advisory Panel To Discuss Vaccines Made From Human Tumor Cell Lines
The Sept. 19 meeting of FDA’s Vaccines and Related Biological Products Advisory Committee comes as several whole-cell cancer vaccines are in Phase III trials.
MedImmune Pipeline Primed To Produce
MedImmune, the biologics arm of performance-challenged AstraZeneca, is poised to lead the parent company into more prosperous times, with positive signals coming from Phase II trials in oncology and asthma and a stake in cancer immunotherapies.